

Bioorganic & Medicinal Chemistry Letters 8 (1998) 1903-1908

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

EFFICIENT SYNTHESIS OF 3'-GLYCOSYLATED LacNAc-BASED OLIGOSACCHARIDES

Yili Ding, Minrou Fukuda and Ole Hindsgaul* The Burnham Institute, La Jolla Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA 92037, U.S.A.

Received 24 April 1998; accepted 11 June 1998

Abstract: LacNAc-based oligosaccharides, including sialyl- $(2\rightarrow 3)$ -LacNAc, dimeric sialyl- $(2\rightarrow 3)$ -LacNAc, trimeric sialyl- $(2\rightarrow 3)$ -LacNAc, β -glucuronyl- $(1\rightarrow 3)$ -LacNAc, and 3-sulfo- β -glucuronyl- $(1\rightarrow 3)$ -LacNAc, were synthesized efficiently from a single protected LacNAc derivative having both OH-3' and 4' unprotected. (© 1998 Elsevier Science Ltd. All rights reserved.

Glycoscience has experienced a surge of interest in recent years as the biological roles of various carbohydrates have been elucidated.¹ This has led to an increased demand for oligosaccharides for biological studies.² Systematic studies on the binding of oligosaccharides with proteins have shown the general trend that the ligand bound to a protein is usually no larger than a tri- or tetrasaccharide. Many ligands are LacNAc derivatives,³ synthetic LacNAc-based oligosaccharides are therefore widely sought for biological studies. Here we report the efficient synthesis of five 3'-glycosylated LacNAc-based oligosaccharides: the parent LacNAc disaccharide 1, sialyl-(2 \rightarrow 3)-LacNAc trisaccharide 2, dimeric sialyl-(2 \rightarrow 3)-LacNAc tetrasaccharide 3, trimeric sialyl-(2 \rightarrow 3)-LacNAc pentasaccharide 4, β -glucuronyl-(1 \rightarrow 3)-LacNAc trisaccharide 5, and 3-sulfo- β -glucuronyl-(1 \rightarrow 3)-LacNAc trisaccharide 6.



The hydrophobic octyl group was selected as the aglycone to simplify the isolation of the deblocked products on C-18 resin.⁴ Glycosylation of octyl 3,6-di-*O*-benzyl-2-acetamido-2-deoxy- β -D-glucopyranoside (7)⁵ with 2,3,4,6-tetra-*O*-acetyl- α -D-glucopyranosyl bromide (8) in the presence of AgOTf and 4 Å molecular sieves

afforded the desired β -linked disaccharide. Subsequent *O*-deacetylation provided disaccharide **9** in 71% yield (two steps). After hydrogenation, the LacNAc disaccharide **1** was obtained in 75% yield. Treatment of compound **9** with 2,2-dimethoxypropane in the presence of *p*-toluenesulfonic acid, followed by benzylation with BnBr/NaH and mildly acidic hydrolytic cleavage of the isopropylidene group afforded the suitably protected glycosyl acceptor **10** in 58% yield (three steps).



Figure 1: (a) Pd/C, H₂, MeOH, 75%; (b) 1. Me₂C(OMe)₂, CSA; 2. NaH, BnBr, *n*-Bu₄NI; 3. AcOH-H₂O (8:2), 52% (three steps).

From diol 10, we synthesized sialyl LacNAc, dimeric sialyl LacNAc and trimeric sialyl LacNAc derivatives for use as substrates for polysialyltransferase.⁶ Glycosylation of 10 with the sialyl donor 11⁷ in acetonitrile at -35 °C for 10 h, in the presence of NIS/TfOH and 3 Å powdered molecular sieves, afforded the desired α -glycoside 12 in 51% yield. *O*-Deacetylation with sodium methoxide in methanol, followed by saponification of the methyl ester and catalytic hydrogenolysis of the benzyl groups (10% Pd/C), yielded the 3'-sialyl LacNAc trisaccharide 2 in 65% yield (three steps).

Using similar procedures, condensation of 10 with the dimeric sialyl donor 13^8 gave the expected tetrasaccharide; after deacetylation and saponification, 14 was isolated in 25% yield (two steps). The ¹H NMR signals at 2.90 ppm (dd, 1H) and 2.70 ppm (dd, 1H) indicated α -glycoside formation. Catalytic hydrogenolysis (10% Pd/C) of the benzyl groups in methanol, followed by purification on Sephadex LH-20, yielded the 3'-dimeric sialyl LacNAc tetrasaccharide 3 in 50% yield.

Coupling the trimeric sialyl acid donor 15° with acceptor 10 for 24 h under the conditions described above, afforded the pentasaccharide. After deacetylation and saponification, pentasaccharide 16 was isolated in 20% yield (three steps). The ¹H NMR signals at 2.91 ppm (dd, 1H), 2.71 ppm (dd, 1H) and 2.55 ppm (dd, 1H) supported the α -glycosidic linkage. After hydrogenation on Pd/C (MeOH/AcOH, 2 days), the final 3'-trimeric sialyl LacNAc 4 was obtained in 40% yield after purification on Sephadex LH-20.

Sulfated and unsulfated β -glucuronyl-(1 \rightarrow 3)-LacNAc trisaccharides were required as substrates and standards in a study on the enzymatic sulfation of β -glucuronyl-(1 \rightarrow 3)-LacNAc derivatives.¹⁰ The glycosylation of **10** with glucuronyl imidate **17**¹¹ was performed at -20 °C in the presence of 0.15 equiv of BF₃/etherate and afforded the 1 \rightarrow 3 linked trisaccharide **18** in 51% yield. After acetylation, the signal for H-4 of the galactosyl



 $\begin{array}{l} \label{eq:Figure 2: (a) NIS (2 equiv), TfOH (0.2 equiv), CH_3CN, 3 Å MS, -35 °C, 2 h, (51%); (b) 1. Pd/C, \\ MeOH/AcOH (1:1), H_2; 2. MeONa/MeOH, 12 h; 3. NaOH/H_2O/MeOH , (1.-3.: 65%); (c) 1. NIS (3 equiv), \\ TfOH (0.2 equiv), CH_3CN, 3 Å MS, -35 °C, 24 h; 2. MeONa/MeOH/H_2O, 24 h, (1.-2.: 25%); (d) Pd/C, \\ MeOH/AcOH, H_2, (50%); (e) 1. NIS (3 equiv), TfOH (0.2 equiv), CH_3CN, 3 Å MS, -35 °C, 24 h; \\ 2. MeONa/MeOH/H_2O, 24 h , (1.-2.: 20%); (f) Pd/C, MeOH/AcOH, H_2, (40%); (g) BF_3/ether (0.15 equiv), \\ CH_2Cl_2, 4 Å MS, -20 °C, 4 h , (51%); (h) 1. NH_2NH_2.AcOH, EtOH, rt, 1 h; 2. SO_3.Et_3N, DMF, 40 °C, \\ 12 h; 3. MeONa/MeOH/H_2O; 4. Pd/C, MeOH, H_2, (1.-4. 55%); (i) BF_3/ether (0.15 equiv), CH_2Cl_2, \\ 4 Å MS, -20 °C, 2 h, (70%); (j) 1. MeONa/MeOH/H_2O; 2. Pd/C, MeOH, H_2, (1.-2. 45%). \\ \end{array}$

moiety was shifted from 4.01 ppm (d, J = 2.7 Hz, 1H) to 4.79 ppm (d, J = 2.7 Hz, 1H), confirming the 1 \rightarrow 3 linkage. Selective removal of the levulinoyl group was achieved with hydrazine-monoacetate. Treatment of the product with excess sulfur trioxide trimethylamine complex in DMF at 40 °C followed by deacetylation with methanolic sodium methoxide, saponification of the methyl ester with sodium hydroxide and catalytic hydrogenolysis (Pd/C, 10%) afforded 3-O-sulfo- β -glucuronyl-(1 \rightarrow 3)-LacNAc 6 in 55% yield after purification on Sephadex LH-20 (four steps). Deprotection of 18 by hydrogenation, deacetylation and saponification gave β -glucuronyl-(1 \rightarrow 3)-LacNAc 5 in 62% yield (three steps).

The perbenzoyl glucuronyl donor 19 was prepared from methyl [2-(trimethylsilyl)ethyl β -D-glucopyranoside]uronate¹¹ in 70% yield by benzoylation, removal of the 2-(trimethylsilyl) ether group, and formation of the trichloroacetimidate. Glycosylation of 10 with 19 in the presence of BF₃/etherate at -20 °C afforded the 1 \rightarrow 3 linked β -glycoside 20 in 70% yield. After catalytic hydrogenolysis (10% Pd/C) of the benzyl groups in methanol, *O*-debenzoylation with sodium methoxide in methanol, and subsequent saponification of methyl ester group with sodium hydroxide, the trisaccharide 5 was obtained in 45% yield (three steps).

In conclusion, the partially protected LacNAc diol **10** was found to be an efficient acceptor for the synthesis of biologically important 3'-glycosylated LacNAc-based oligosaccharides.

Acknowledgment

This work was supported by P01CA 71932 from The National Institutes of Health.

References and notes

- 1. Fukuda, M. in *Molecular Glycobiology*; Fukuda, M.; Hindsgaul, O., Eds.; IRL: Oxford, 1994; pp 1-52.
- 2. Lemieux, R. U. Chem. Soc. Rev. 1989, 18, 347.
- Bundle, D. R.; Baumann, H.; Brisson, J. R.; Gagne, S. M.; Zdanov, V.; Cygler, M. Biochemistry 1994, 33, 5183.
- 4. Palcic, M. M.; Heerze, L. D.; Pierce, M.; Hindsgaul. O. Carbohydr. Res. 1988, 5, 49.
- 5. Malet, C.; Hindsgaul, O. Carbohydr. Res. 1997, 303, 567.
- 6. Fukuda, M.; Ding, Y.; Hindsgaul, O. unpublished results.
- 7. Roy, R.; Andersson, F. O.; Letellier, M. Tetrahron Lett. 1992, 33, 6053.

- 9. Ishida, H. K.; Ishida, H.; Kiso, M.; Hasegawa, A. J. Carbohydr. Chem. 1994, 13, 655.
- 10. Ong, E.; Yeh, J. C.; Ding, Y.; Hindsgaul, O.; Fukuda, M. J. Biol. Chem. 1998, 273, 5190.
- 11. Isogai, Y.; Kawase, T.; Ishida, H.; Kiso, M.; Hasegawa, A. J. Carbohydr. Chem. 1996, 15, 1001.

Spectral data for selected new compounds:

1, ¹H NMR (300 MHz, CD₃OD): δ 4.38 (1H, J = 7.6 Hz, H-1), 4.40 (1H, J = 7.6 Hz, H-1'), 1.95 (s, 3H, NHCOCH₃), 0.88 (t, 3H, J = 6.6 Hz, CH₃).

2, ¹H NMR (300 MHz, CD₃OD): δ 4.44 (d, 1H, J = 7.8 Hz, H-1), 4.36 (d, 1H, J = 8.1 Hz, H-1'), 4.04 (dd, 1H, $J_{3',2'}$ = 9.6 Hz, $J_{3',4'}$ = 3 Hz, H-3'), 2.75 (dd, 1H, H-3"eq), 2.00 (s, 3H, NHCOCH₃), 1.95 (s, 3H, NHCOCH₃), 0.89 (t, 3H, J = 6.6Hz, CH₃); ¹³C NMR (300 MHz, CD₃OD): δ 102.9, 101.8, 100.9 (C-1, C-1' and C-1").

3, ¹H NMR (300 MHz, CD₃OD): δ 4.44 (d, 1H, J = 7.2 Hz, H-1), 4.38 (d, 1H, J = 8.0 Hz, H-1'), 2.48 (m, 2H, H-3"eq and H-3"eq), 2.02 (s, 6H, 2×NHCOCH₃), 1.96 (s, 3H, NHCOCH₃), 0.90 (t, 3H, J = 6.6 Hz, CH₃); ESMS: m/z 1077 [M]⁺.

4, ¹H NMR (500 MHz, CD₃OD): δ 4.40 (d, 1H, *J* = 7.7 Hz, H-1), 4.38 (d, 1H, *J* = 8.0 Hz, H-1') 2.89 (dd, 1H), 2.49 (dd, 1H), 2.45 (dd, 1H), 2.04 (s, 3H, NHCOCH₃), 2.03 (s, 3H, NHCOCH₃), 2.01 (s, 6H, 2×NHCOCH₄), 0.89 (t, 3H, *J* = 6.7 Hz, CH₃); ESMS: *m/z* 1367 [M]⁺.

5, ¹H NMR (300 MHz, CD₃OD): δ 4.68 (d, 1H, *J* = 7.8 Hz, H-1), 4.52 (d, 1H, *J* = 7.6 Hz, H-1'), 4.50 (d, 1H, *J* = 7.0 Hz, H-1"), 4.11 (d, 1H, *J* < 1 Hz, H-4'), 1.95 (s, 3H, NHCOCH₃), 0.89 (t, 3H, *J* = 6.6 Hz, CH₃); ¹³C NMR (300 MHz, CD₃OD): δ 105.4, 105.4, 102.8 (C-1, C-1' and C-1"); ESMS: *m*/*z* 670 [M]⁺.

6, ¹H NMR (300 MHz, CD₃OD): δ 4.65 (d, 1H, H-1), 4.49 (m, 2H, H-1' and H-1"), 4.30 (t, 1H, H-3"), 4.11 (d, 1H, J < 1 Hz, H-4"), 1.95 (s, 3H, NHCOCH₃), 0.89 (t, 3H, J = 6.6 Hz, CH_3); ¹³C NMR (300 MHz, CD₃OD): δ 105.4, 105.3, 102.9 (C-1, C-1' and C-1"); ESMS: m/z 772 [M]⁺.

9, ¹H NMR (300 MHz, CD₃OD): δ 4.45 (d, 1H, *J* = 7.8 Hz, H-1'), 4.39 (d, 1H, *J* = 7.8 Hz, H-1), 1.91 (s, 3H, NHCOCH₃), 0.88 (t, 3H, *J* = 6.9 Hz, CH₃); ¹³C NMR (300 MHz, CD₃OD): δ 104.4, 102.8 (C-1 and C-1').

10, ¹H NMR (300 MHz, CD₃OD): δ 4.38 (d, 1H, J = 7.2 Hz, H-1), 4.38 (d, 1H, J = 7.3 Hz, H-1'), 1.90 (s, 3H, NHCOCH₃), 0.90 (s, 3H, J = 6.6 Hz, CH₃); ¹³C NMR (300 MHz, CD₃OD): δ 104.3, 102.8 (C-1, C-1').

14, ¹H NMR (300 MHz, CD₃OD): δ 7.1-7.4 (m, 20H, 4×CH₂*Ph*), 2.64 (dd, 1H, H-3'eq), 2.59 (dd, 1H, H-3'''eq), 2.0 (s, 6H, 2×NHCOCH₃), 1.81 (s, 3H, NHCOCH₃), 0.90 (s, 3H, CH₃); ¹³C NMR (300 MHz, CD₃OD): δ 104.9, 103.8, 103.0, 102.5 (C-1, C-1', C-2'' and C-2''').

16, ¹H NMR (300 MHz, CD₃OD): δ 7.1-7.4 (m, 20H, 4×CH₂*Ph*), 2.90 (dd, 1H, H-3"eq), 2.70 (dd, 1H, H-3"eq), 2.58 (dd, 1H, H-3"eq), 2.00 (s, 6H, 2×NHCOCH₃), 1.98 (s, 3H, NHCOCH₃), 1.80 (s, 3H, NHCOCH₃); 0.89 (t, 3H, *J* = 6.6 Hz, CH₃); ¹³C NMR (300 MHz, CD₃OD): δ 104.0, 103.5, 103.0, 102.8, 102.2 (C-1, C-1', C-2". C-2"and C-2"").

18, ¹H NMR (300 MHz, CD₃OD): δ 5.59 (t, 1H, J = 9.0 Hz, H-2"), 5.31 (d, 1H, J = 8.1 Hz, H-1"), 5.21 (t, 1H, J = 9.9 Hz, H-3"), 5.12 (d, 1H, J = 10.8 Hz, H-4"), 4.59 (d, 1H, J = 8.1 Hz, H-1'), 4.43 (d, 1H, J = 8.1 Hz, H-1), 4.01 (d, 1H, J = 2.7 Hz, H-4'), 3.59 (s, 3H, OCH₃), 2.06 (s, 3H, COCH₃), 1.99 (s, 3H, OCOCH₃), 1.96 (s, 3H, NHCOCH₃), 0.89 (t, 3H, CH₃); ¹³C NMR (300 MHz, CD₃OD): δ 102.51, 101.49, 99.34 (C-1, C-1' and C-1").

20, ¹H NMR (300 MHz, CD₃OD): δ 6.03 (t, 1H, J = 9.9 Hz), 5.58 (t, 1H, J = 9.0 Hz), 5.57 (d, 1H, J = 7.5 Hz, H-1"), 5.13 (d, 1H, J = 10.8 Hz, H-5"), 4.60 (d, 1H, J = 7.5 Hz, H-1), 4.30 (d, 1H, J = 7.5 Hz, H-1'), 3.50 (s, 3H, OCH₃), 1.96 (s, 3H, NHCOCH₃), 0.88 (t, 3H, J = 6.0 Hz, CH₃); ¹³C NMR (300 MHz, CD₃OD): δ 103.86, 102.99, 102.76 (C-1, C-1' and C-1").